Bernstein Sticks to Its Buy Rating for Novartis AG (NOVN)
'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
CMB International: Maintains INNOVENT BIO's "Buy" rating, with the Target Price raised to 57.67 HKD.
CMB International has released a research report stating that it maintains a "Buy" rating for INNOVENT BIO (01801), being bullish on the global potential of INNOVENT's Innovative Drugs pipeline, and has raised the target price to HKD 57.67 (previous value: HKD 55.21; WACC: 9.5%, perpetual growth rate: 3.5%). The company has licensed the global rights of the new DLL3ADC (IBI3009) to Roche, receiving an upfront payment of USD 80 million and up to USD 1 billion in milestone payments and sales sharing. The drug is expected to receive IND approval for global Phase 1 research in December 2024. Regarding the DLL3 target, besides
Express News | The second phase of the Peking integrated circuit equipment industry investment and merger Fund has been established with a contribution of 2.5 billion.
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
Here's Why Novartis (NVS) Is a Strong Growth Stock
Novartis Reports Positive Results for Intrathecal Zolgensma
Novartis AG (NVS.US): Its new experimental drug improves motor functions in children with SMA.
Novartis AG stated that their new experimental drug improved motor function in children with spinal muscular atrophy (SMA) in a late-stage study.
Reported Earlier, Novartis Reports Topline Results From Phase III STEER Study; Study Met Its Primary Endpoint
Novartis Experimental Medicine Shows Improvement in Spinal Muscular Atrophy
Novartis Says New Drug Helps Children With Rare Spinal Condition
Novartis' Late-stage Study for Spinal Muscular Atrophy Therapy Meets Primary Endpoint
Novartis AG (NVS): Among the Cheap Healthcare Stocks to Buy Heading Into 2025
Sector Update: Health Care Stocks Lower in Late Afternoon Trading
Sector Update: Health Care
Novartis to Face Whistleblower Case on MS Drug Kickbacks: Report
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, US Appeals Court Rules
Novartis Must Face Claims Alleging Kickbacks for MS Drug Promotion, Appeals Court Rules